Showing results (191-200 of 217) with videos related to

Sort By:
Pageof 22
Marine Drugs|November 3, 2020
Marine-Derived <i>Penicillium purpurogenum</i> Reduces Tumor Size and Ameliorates Inflammation in an Erlich Mice ModelAmanda Mara Teles, Leticia Prince Pereira Pontes, Sulayne Janayna Araújo Guimarães, et al.
Pharmacoepidemiology and Drug Safety|July 8, 2015
Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU ProjectConsuelo Huerta, Victoria Abbing-Karahagopian, Gema Requena, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2016
<sup>18</sup>F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized TrialMiguel Quintela-Fandino, Ana Lluch, Luis Manso, et al.
Scientific Reports|May 10, 2020
Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control studyNerea Fernández de Larrea-Baz, Beatriz Pérez-Gómez, Ángel Guerrero-Zotano, et al.
Therapeutic Advances in Medical Oncology|June 18, 2019
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medicationMeritxell Bellet, Faten Ahmad, Rafael Villanueva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2012
Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancerJosé Baselga, José Getúlio Martins Segalla, Henri Roché, et al.
Oncotarget|April 21, 2017
Critically short telomeres and toxicity of chemotherapy in early breast cancerMiguel Quintela-Fandino, Nora Soberon, Ana Lluch, et al.
Targeted Oncology|October 7, 2020
Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)Juan Manuel Sepúlveda-Sánchez, Miguel Gil-Gil, Miriam Alonso-García, et al.
The Lancet. Oncology|December 16, 2019
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trialAleix Prat, Cristina Saura, Tomás Pascual, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2021
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL studyZsuzsanna Kahan, Miguel Gil-Gil, Manuel Ruiz-Borrego, et al.
Pageof 22